389
Participants
Start Date
June 30, 2015
Primary Completion Date
September 29, 2018
Study Completion Date
September 29, 2018
Prospective Phase Rifaximin-α 550mg
Prospective data collection of all patients receiving rifaximin-α 550 mg from the point of study entry.
Prospective Phase No Rifaximin-α 550mg
Prospective data collection of all patients not receiving rifaximin-α 550 mg from the point of study entry.
Retrospective Phase
Review of medical records and electronic hospital admissions data for patients with HE who have not received rifaximin-α 550 mg during the previous 12 months.
Queen Elizabeth Hospital, Birmingham
Lead Sponsor
Norgine
INDUSTRY